Au­to­lus eyes No­vem­ber for po­ten­tial US ap­proval of Tecar­tus ri­val

Au­to­lus Ther­a­peu­tics is ex­pect­ing an FDA de­ci­sion on Nov. 16 for obe­cab­ta­gene au­toleu­cel (obe-cel), its CAR-T hope­ful that would ri­val Gilead’s Tecar­tus in adult acute …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER